Using Super-GDF9 to Improve Oocyte Quality in In Vitro Fertilization
Official title: Exploratory In-vitro Study Evaluating the Addition of Super-GDF9 During Capacitation-in-vitro Maturation (CAPA-IVM) of Donated Human Cumulus-oocyte Complexes (COCs) Derived From Small Antral Follicles
Run by Mỹ Đức Hospital · NCT06766604 · Data updated 2026-11-12
This study is testing if adding Super-GDF9 can help improve egg quality during a specific fertility treatment for women with PCOS who are looking for a safer and more affordable alternative to traditional IVF.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 38 Years |
| Sex | Women only |
| Enrollment | 9 (estimated) |
| Sponsor | Mỹ Đức Hospital Academic / other |
| Locations | 1 site (Ho Chi Minh City) |
| Status | Recruiting |
| Started | January 10, 2025 |
| Main results expected | February 17, 2025 |
| Study ends | April 30, 2026 |
| Registry record updated | July 10, 2025 |
| Trial ID | NCT06766604 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women aged 18 to 38 with PCOS and a sufficient number of antral follicles.
✕Probably not a fit
Patients with severe male factor infertility or significant uterine abnormalities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of Super-GDF9 supplementation during CAPA-IVM, an assisted reproductive technology aimed at improving oocyte quality for women with conditions like PCOS. The study focuses on high-risk patients who may benefit from a safer and more cost-effective alternative to conventional IVF. By enhancing the culture process with growth factors found in follicular fluid, the trial aims to increase the number of good-quality embryos and improve cumulative clinical pregnancy rates. Participants will be women aged 18 to 38 with specific eligibility criteria related to their ovarian health and PCOS diagnosis.
Why it matters
Potential benefit: If successful, this approach could lead to higher quality oocytes and improved pregnancy outcomes for women undergoing IVF.
How similar studies have gone: While similar approaches have shown promise, this specific use of Super-GDF9 in CAPA-IVM is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Women between the ages of 18 and 38 years (both inclusive) 2. BMI ≤ 32 kg/m2 3. PCOS women according to the Rotterdam criteria (2003) 4. Indicating CAPA-IVM treatment. 5. Serum AMH ≥ 4 ng/mL (28.57 pmol/L) at screening and having at least 24 antral follicles in two ovaries by transvaginal ultrasound at the time of CAPA-IVM indication 6. Willing to donate COCs for research purposes 7. Agreeing for frozen embryo 8. Signed informed consent before any study-related procedures Exclusion Criteria: 1. Known endometrioma or grade 3-4 endometriosis according to ASRM classification 2. Uterine abnormalities 3. Couples with severe male factor (sperm concentration \<5 million/ml, motility \< 10%), surgical sperm retrieval. 4. Previous history of unexplained immature oocytes after IVF treatment 5. Cycles using donor oocytes
Where it's running
-
My Duc Hospital
Ho Chi Minh City, Vietnam Recruiting
Study contacts
- Principal investigator: Lan N Vuong — University of Medicine and Pharmacy at Ho Chi Minh City
- Study coordinator: Kha T Huynh
- Email: kha.ht@myduchospital.vn
- Phone: +84946699470
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Day-4 embryo defragmentation to improve blastocyst formation and pregnancy outcomes
This study tests whether removing cytoplasmic fragments from Day-4 morula-stage embryos helps people undergoing ICSI get more blastocysts and better pregnancy chances.
-
How a mother's immune system accepts pregnancy in the first trimester
We will test how the immune system changes in the first trimester in people undergoing IVF to see which immune patterns support implantation and help prevent early miscarriage.
-
Ovarian PRP injections to try to improve embryo quality
This study tries ovarian platelet-rich plasma (PRP) injections to see if they improve embryo development for people doing IVF.
-
Using antioxidant-rich media to improve embryo quality in IVF
This study is testing if using a special culture solution with antioxidants can help improve the quality of embryos for people undergoing IVF.
-
GnRH agonist for luteal support after GnRH agonist ovulation trigger in IVF/ICSI
This tests whether using a GnRH agonist to trigger ovulation and continuing a GnRH agonist for luteal support improves pregnancy outcomes and reduces OHSS for people undergoing IVF or ICSI.
-
Using Metformin to Improve Live Birth Rates in Women with Prediabetes Undergoing IVF
This study is testing if taking metformin before IVF can help women with prediabetes have a healthier chance of getting pregnant and having a baby.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.